Table of Contents
Overview
Catalyst
Summary
Table of Contents
Table of figures
Table of tables
Company Structure
Company Overview and Key Facts
Business Description
History
M&A
The Analytica Group
TEAMM Pharmaceuticals
Company Financials
Stock Market Performance
P&L
Balance Sheet
Cash Flow
Business Segment Performance
Geographic Segment Performance
Products & Services
Marketed Products
Alcortin
Histex Liquid
Novacort
RespiTANN
Pipeline Products
In-house Pipeline
BiovaxID
Revimmune
Collaboration Pipeline
AllerNase
SinuNase
Emezine
Historical Product Sales
AC Forecast Product Sales
Competitors and Strategic Business Relationships
Key Competitors
Key Suppliers
Key Clients
Shareholding Structure
Strategy
Company View
Corporate Strategy
SWOT Analysis
Overview
Strengths
In-house service capabilities
Weaknesses
SinuNase's failure in Phase III trial
Opportunities
Results from BiovaxID's pivotal Phase III trials
Acquisition of Revimmune
Threats
Lack of regulatory pathway for patient-specific active immunotherapies in the US
Costly and time consuming FDA approval process
Value Chain Analysis
Overview
Product Development
Manufacturing
Sales
Scorecard
Overview
Scorecard Analysis
Key Employees
List of Key Employees
Key Employee Biographies
Francis E O'Donnell
Steven R Arikian
Alan M Pearce
Samuel S Duffey
Financial and Operational Overview
Financial and Operational Overview
APPENDIX
Ask the analyst
It consulting
Disclaimer
List of Tables
Table 1: Accentia Biopharmaceuticals - Key Facts
Table 2: Accentia Biopharmaceuticals- Year-End Share Price and Market Capitalization, 2002-2006 ($)
Table 3: Accentia Biopharmaceuticals- Key Events Impacting Share Price Performance
Table 4: Accentia Biopharmaceuticals- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
Table 5: Accentia Biopharmaceuticals- Operating Cost Ratio Analysis, 2002-2006 (% of total revenues)
Table 6: Accentia Biopharmaceuticals- Balance Sheet, 2002-2006 ($ Mn)
Table 7: Accentia Biopharmaceuticals- Cash Flow, 2002-2006 ($ Mn)
Table 8: Accentia Biopharmaceuticals- Revenue Breakdown by Division, 2002-2006 ($ Mn)
Table 9: Accentia Biopharmaceuticals- Geographic Breakdown, 2002-2006 ($ Mn)
Table 10: Accentia Biopharmaceuticals- Marketed Products
Table 11: Accentia Biopharmaceuticals- In-house Pipeline Products
Table 12: Accentia Biopharmaceuticals- Collaboration Pipeline
Table 13: Accentia Biopharmaceuticals- Key Strategic Revenues, 2002-2006 ($ Mn)
Table 14: Accentia Biopharmaceuticals- Key Strategic Revenues, 2006-2010 ($ Mn)
Table 15: Accentia Biopharmaceuticals- Key Competitors
Table 16: Accentia Biopharmaceuticals- Key Suppliers
Table 17: Accentia Biopharmaceuticals- Key Clients
Table 18: Accentia Biopharmaceuticals - Key Shareholders
Table 19: Accentia Biopharmaceuticals- SWOT Analysis Summary
Table 20: Accentia Biopharmaceuticals- Value Chain Analysis
Table 21: Accentia Biopharmaceuticals- Scorecard
Table 22: Accentia Biopharmaceuticals- Key Employees
Table 23: Accentia Biopharmaceuticals - Financial and Operational Overview
List of Figures
Figure 1: Accentia Biopharmaceuticals- Operating Revenue/Cost Analysis, 2002-2006 ($ Mn)
